Phase II trials and retrospective studies have also demonstrated that treating BM in patients with EGFR-mutant NSCLC with EGFR-TKIs without the use of upfront radiation produces better efficacy than treatment including upfront radiation9, 10. Here, EGFR is linked to non-small cell lung carcinoma.